Discover how protein, fiber, carbohydrates, and fats biologically shape hunger and fullness through measurable changes in gut hormones and central appetite circuits.

Not all fiber works the same. Discover how viscosity, fermentation, and microbiome diversity determine whether dietary fiber ...

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...

Appetite doesn't begin in the stomach. It begins in the brain. When you start a GLP-1 medication, the first shifts happe ...

Over the long term, Levin expects oral GLP-1s to gain favor over injectables. Most patients prefer pills to injections, and ...

Pharmaceutical companies facing increasing demand for GLP-1 agonist receptors are struggling to minimise their impact on the environment. Mahima Adey reports As demand for glucagon-like peptide-1 (GLP ...

The latest wellness craze involves injecting these molecules for athletic performance, longevity and more. Scientists say the research isn't keeping pace with the health claims.

Glucagon-like peptide-1 receptor agonist use was associated with increased risk of telogen effluvium and androgenetic alopecia.

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

Novo vs. Lilly. Why are investors upset? Basically, because the point of the trial was for Novo Nordisk to demonstrate that a 2.4/2.4 mg dose of CagriS ...

Demand from patients for obesity medication is unrelenting. So, too, is the battle over who gets to develop and distribute ...